ESR1 and neoplasm: We also paired paclitaxel or sabizabulin with lapatinib in AU565 (ER−/PR−/HER2+; lapatinib-sensitive) and JIMT (ER−/PR−/HER2+; lapatinib-resistant) cells [47,48], and found that sabizabulin, but not paclitaxel, was synergistic with lapatinib to inhibit HER2+ tumor cell growth.